Physician

Ajay Vallakati, M.D.

According to 2025 Medicare claims, Ajay Vallakati, M.D. (NPI: 1699905323) practices advanced heart failure and transplant cardiology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is OSU INTERNAL MEDICINE, LLC (NPI: 1740231448; TIN: 311369596) and primary practice location at 43210-1240. Vallakati is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Vallakati's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 728 traditional Medicare patients, billed 1,166 HCPCS/CPT codes, and received $57,091 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,676 prescription claims across 436 beneficiaries totaling $3,505,153 in drug costs, led by Vyndamax (Tafamidis). DME data shows 143 claims. Open Payments data shows 1 records totaling $16. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $3,752 to $3,505,153. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,306 to $3,184.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	212	326	$21,087
2018	514	1,086	$78,537
2019	467	1,132	$88,463
2020	427	1,072	$81,736
2021	467	1,167	$91,472
2022	403	920	$71,602
2023	397	901	$72,604
2024	728	1,166	$57,091

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	18	99	$3,752
2016	26	103	$2,049
2017	60	206	$73,520
2018	169	884	$45,650
2019	308	1,885	$289,018
2020	325	2,115	$735,566
2021	332	2,048	$1,059,322
2022	370	2,514	$1,365,172
2023	394	2,664	$1,944,684
2024	436	2,676	$3,505,153

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	45	$1,897
2018	N/R	53	$2,559
2019	N/R	110	$3,430
2020	N/R	82	$2,651
2021	N/R	217	$11,081
2022	37	165	$4,335
2023	24	250	$5,870
2024	11	143	$2,393

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	29	32	$96
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	57	204	$86
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	174	202	$73
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	40	42	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	396	471	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	96	3,420	$2,667,156
Entresto	Sacubitril/Valsartan	192	11,321	$238,082
Camzyos	Mavacamten	27	785	$223,352
Eliquis	Apixaban	128	7,425	$143,077
Jardiance	Empagliflozin	115	5,216	$93,450

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	50	$873
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	37	$640
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	36	$477
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	20	$403

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$16	Edwards Lifesciences Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ajay Vallakati, M.D.?

Tedicare shows public-source Medicare data for Ajay Vallakati, M.D. (NPI 1699905323), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ajay Vallakati, M.D. have ACO affiliation data?

Ajay Vallakati, M.D. is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Ajay Vallakati, M.D.?

Ajay Vallakati, M.D. is linked to OSU INTERNAL MEDICINE, LLC (billing NPI 1740231448) in the available physician profile data.

Does Ajay Vallakati, M.D. have Open Payments data?

Ajay Vallakati, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.